Clinical trial NCT06517641: Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
Official title: A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Haploidentical Related, Partially HLA-Mismatched, or Matched Unrelated Bone Marrow for Newly Diagnosed Patients With Severe Aplastic Anemia
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Severe Aplastic Anemia
Lead sponsor: Medical College of Wisconsin
Sponsor class: OTHER
Collaborators: name: National Heart, Lung, and Blood Institute (NHLBI)
name: National Cancer Institute (NCI)
name: Sanofi
First posted: 2024-07-24
Enrollment: 60
Sex: ALL
Minimum age (years): 3
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This is a parallel cohort study comprised of two cohorts - patients receiving haploidentical donor transplant and patients receiving unrelated donor transplant. The goal is 60 participants in total who initiate the protocol-specified conditioning regimen, 30 in each of the haploidentical and unrelated donor transplant cohorts. Additional participants may be screened, consented, and registered in order to reach accrual goals.
Primary purpose: TREATMENT

Brief summary: BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated.

Detailed description: This study is a prospective, multicenter Phase II study of hematopoietic stem cell transplantation for previously untreated patients with severe aplastic anemia (SAA). Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. Patients with aplastic anemia have low white blood cells (cells which fight infection), low red blood cells (cells that carry oxygen throughout the body), and low platelets (cells that help form clots and prevent bleeding). Treatments for SAA seeks to repair this abnormal immune system attack and allow the bone marrow to make the normal amount of blood cells. This can be done with a bone marrow transplant or with medications to suppress the immune system.

Historically, transplant therapy for SAA has been reserved for patients under 40 years old who had an available fully matched related donor. The standard treatment for older patients with SAA and patients who do not have a fully matched related donor has been treatment using transfusions, medications that suppress the immune system (immunosuppressive therapy, IST), and medications that try to stimulate the bone marrow to produce more cells. For these patients, transplant was used only if a patient did not respond to these interventions. However, progress has made transplantation safer and allowed for half-matched related donor or full or partially-matched unrelated donors to be used with success rates similar to fully matched related donors in many situations. The goals of this study are to determine if patients with SAA who have not received previous treatment for SAA can be treated effectively with transplant as their first SAA therapy.

This is a parallel cohort study comprised of two cohorts based on donor selection: haploidentical related donors and unrelated donors. The accrual goal is 30 participants enrolled and starting protocol-specified conditioning in each cohort, yielding 60 participants in total. Participants will be treated with a reduced-intensity preparative regimen of fludarabine (150 mg/m2), cyclophosphamide (29 mg/kg), low dose total body irradiation (TBI, 400 cGy), and Thymoglobulin® (4.5 mg/kg). Bone marrow will be collected from donors and fresh (not cryopreserved) cells will be given to patients. GVHD prophylaxis will be with post-HSCT cyclophosphamide (100 mg/kg), tacrolimus, and mycophenolate mofetil (MMF). All patients will receive the same conditioning regimen and GVHD prophylaxis. Participants will be followed for 1 year post-transplant.

Eligibility criteria: Inclusion Criteria:

1. Age 3 years to 75 years
2. Confirmed diagnosis of acquired SAA defined as:

   a. Bone marrow cellularity \< 25% or variable marrow cellularity but with \< 30% residual hematopoietic cells deemed HYPOcellular for age AND b. Two (2) out of 3 of the following (in peripheral blood). i. Neutrophils \< 0.5 x109/L ii. Platelets \< 20 x109/L iii. Reticulocyte count \< 20 x109/L (\< 60 x 109/L using an automated analysis)
3. No suitable fully matched related donor as per Investigator's discretion (6/6 match for HLA A and B at intermediate or high-resolution and DRB1 at high-resolution using deoxyribonucleic acid \[DNA\]-based typing) available.
4. Available donor as defined in the protocol.
5. Participant and/or legal guardian must sign informed consent.
6. Adequate organ function defined by institutional transplant standards or defined as below:

   1. Cardiac: Left ventricular ejection fraction (LVEF) at rest \> 40% with no clinical signs of cardiac failure. For participants aged \< 13 years, shortening fraction (SF) ≥ 26% by echocardiogram or multigated acquisition (MUGA) may be substituted for LVEF.
   2. Hepatic: Total bilirubin \< 2.0 mg/dL unless Gilbert's disease is present
   3. Renal: For participants \> 13.0 years of age at the time of enrollment: estimated creatinine clearance (CrCl) \> 60 mL/minute (per institutional standard). For participants \< 13.0 years of age at enrollment: glomerular filtration rate (GFR) estimated by the updated Schwartz formula ≥ 90 mL/min/1.73 m2. If the estimated GFR is \< 90 mL/min/1.73 m2, then renal function must be measured by 24-hour creatinine clearance or nuclear GFR, and must be \> 50 mL/min/1.73 m2.
   4. Pulmonary:

   i. For participants \> 13.0 years of age: Diffusing capacity of the lung for carbon monoxide (DLCO, corrected/adjusted for hemoglobin \[Hb\]) \> 50%, or Spirometry with forced expiratory volume 1 (FEV1) \> 50% predicted (without administration of bronchodilator) and forced vital capacity (FVC) \> 50% predicted.

   ii. For participants \< 13.0 years of age unable to perform pulmonary function tests (PFTs) due to age or developmental ability: (1) no evidence of dyspnea at rest and (2) no need for supplemental oxygen and (3) O2 saturation \> 92% on room air at sea level (with lower levels allowed at higher elevations per established center standard of care \[e.g., Utah, 4,200 feet above sea level, does not give supplemental oxygen unless below 90%\]).
7. Karnofsky or Lansky performance status ≥ 60%.
8. Females and males of childbearing potential must agree to practice 2 effective methods of contraception at the same time or agree to abstinence.

Exclusion Criteria:

1. Inherited bone marrow failure syndromes such as Fanconi anemia and short telomere syndromes must be ruled out according to center standards. It is recommended that functional testing for Fanconi Anemia (di-epoxybutane \[DEB\] chromosomal breakage analysis) and telomere length assessment be performed. If available, genetic panels for inherited bone marrow failure syndromes can be considered as an alternative to functional testing.
2. Clonal cytogenetic abnormalities consistent with pre-MDS or MDS on marrow examination (e.g., monosomy 7 and other MDS-defining changes per recent pathology guidelines).
3. Formal diagnosis of MDS by World Health Organization (WHO) 2022 or International Consensus Classification (ICC).
4. Recipient positive for HLA antibodies against a mismatched HLA in the selected donor determined by the presence of donor specific HLA antibodies (DSA) to any mismatched HLA allele/antigen at any of the following loci (HLA-A, -B, -C, -DRB1, DRB3, DRB4, DRB5, -DQA1, -DQB1, -DPA1, -DPB1) with median fluorescence intensity (MFI) \>3000 by microarray-based single antigen bead testing. In patients receiving red blood cell or platelet transfusions, DSA evaluation must be performed or repeated post-transfusion and immediately prior to initiation of recipient preparative regimen to ensure there is confirmation of no DSA to the selected donor when conditioning starts.
5. Prior desensitization attempt for HLA antibodies to chosen donor. Any intervention with the sole intent to reduce the level of HLA DSA, (e.g., plasmapheresis, intravenous immunoglobulin \[IVIG\], MMF, etc.) would constitute a desensitization attempt.
6. Prior treatment for SAA (e.g., immunosuppressive therapy using ATG, calcineurin inhibitors \[CNIs\], thrombopoietin receptor agonists or androgens). Short courses of steroids or IVIG that were not explicitly administered for SAA therapy will be allowed.
7. Prior allogeneic stem cell transplant.
8. Prior solid organ transplant.
9. Known life-threatening reaction (i.e., anaphylaxis) to Thymoglobulin® (Sanofi) that would prohibit use for the participant as this study requires use of the Thymoglobulin® (Sanofi) preparation of ATG.
10. Uncontrolled bacterial, viral, or fungal infection at the time of enrollment. Uncontrolled is defined as currently taking medication and with progression or no clinical improvement on adequate medical treatment.
11. Female participants who are pregnant, as detected using a pregnancy test as per institutional practice, or breast-feeding.
12. Prior malignancies except resected basal cell carcinoma or treated cervical carcinoma in situ. Cancer treated with curative intent \> 5 years previously will be allowed. Cancer treated with curative intent ≤ 5 years previously will not be allowed unless approved by the Protocol Chairs and/or Protocol Officer.

Of note, participants with seropositivity for the human immunodeficiency virus (HIV) may be considered if viral load is undetectable. Similarly, carriers of hepatitis B (HepB) or hepatitis C (HepC) may not have a detectable viral load of HepB virus or HepC virus.

Participants with HIV that is well-controlled on combination antiretroviral therapy and no AIDS related complications within the past 12 months are eligible.

Infections other than HIV:

* Prior infections must be controlled
* HepB participants are eligible if on effective suppressive therapy and otherwise meet inclusion/exclusion criteria
* HepC participants are eligible if otherwise meet inclusion/exclusion criteria

Primary outcomes:
measure: Graft versus host disease (GVHD)-free failure-free survival (GFFS) at One year
timeFrame: 1 year after initiation of conditioning
Secondary outcomes:
measure: Percentage of Participants with Overall survival (OS) at One year post conditioning
timeFrame: 1 year after initiation of conditioning
measure: Percentage of Participants with Failure-Free Survival (FFS) at One year post conditioning
timeFrame: 1 year after initiation of conditioning
measure: Participants Alive and Engrafted at One year post conditioning
timeFrame: 1 year after initiation of conditioning
measure: Percentage of Participants with Neutrophil Recovery post-transplant
timeFrame: Day 28 and Day 56 post-HSCT
measure: Percentage of Participants with Red Blood Cell Recovery post-transplant
timeFrame: Day 100, Day 180, and Day 365 post-HSCT
measure: Percentage of Participants with Platelet Recovery post-transplant
timeFrame: Day 100 post-HSCT
measure: Percentage of Participants with Primary Graft Failure post-transplant
timeFrame: Day 56 post-HSCT
measure: Percentage of Participants with Secondary Graft Failure post-transplant
timeFrame: 1 year post-HSCT
measure: Percentage of Participants with any Graft Failure (primary or secondary) post-transplant
timeFrame: 1 year post-HSCT
measure: Participants with Hematologic Response post-transplant
timeFrame: Day 100, Day 180, and Day 365 post-HSCT
measure: Percentage of participants with Grades II-IV and III-IV Acute GVHD at Day 100 post-transplant
timeFrame: Day 100 post-HSCT
measure: Percentage of participants with Chronic GVHD at One year post-transplant
timeFrame: Day 365 post-HSCT
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
city: Duarte
country: United States
facility: City of Hope
state: California
city: Los Angeles
country: United States
facility: University of California, Los Angeles
state: California
city: Stanford
country: United States
facility: Stanford University
state: California
city: Tampa
country: United States
facility: Moffitt Cancer Center
state: Florida
city: Atlanta
country: United States
facility: Emory Winship Cancer Institute
state: Georgia
city: Atlanta
country: United States
facility: Blood and Marrow Transplant Center at Northside Hospital
state: Georgia
city: Westwood
country: United States
facility: University of Kansas Medical Center
state: Kansas
city: Baltimore
country: United States
facility: Johns Hopkins University
state: Maryland
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Detroit
country: United States
facility: Karmanos Cancer Institute
state: Michigan
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
city: Charlotte
country: United States
facility: Levine Cancer Institute
state: North Carolina
city: Durham
country: United States
facility: Duke University Health System
state: North Carolina
city: Columbus
country: United States
facility: The Ohio State University
state: Ohio
city: Oklahoma City
country: United States
facility: University of Oklahoma
state: Oklahoma
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
city: Nashville
country: United States
facility: Vanderbilt University
state: Tennessee
city: Salt Lake City
country: United States
facility: Huntsman Cancer Institute
state: Utah
city: Seattle
country: United States
facility: Fred Hutchinson Cancer Center
state: Washington
city: Milwaukee
country: United States
facility: Medical College of Wisconsin
state: Wisconsin
Study officials:
References: